Brought to you by 
Cubist gets option to acquire pain management biotech Adynxx; option not exercised
26 Aug 2020
Executive Summary
In exchange for a $20mm up-front fee, acute care product company Cubist Pharmaceuticals Inc. has obtained the exclusive option to buy closely held Adynxx Inc. (pain management) following receipt of the Phase II data on Adynxx’s lead pain drug AYX1 (the proof-of-concept trial enrolled its first patient concurrent with this announcement). Should Cubist exercise the option, it would pay $40mm plus development, regulatory, and sales earn-outs.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cubist gets option to acquire pain management biotech Adynxx; option not exercised
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice